Find uplifting stories about heroes, innovations, and solutions
7 results for "teplizumab"
Australia just approved the first treatment in 100 years that can delay type 1 diabetes before symptoms even appear. Teplizumab gives families precious extra time without insulin therapy, fear, and constant medical monitoring.
A groundbreaking treatment called teplizumab can delay type 1 diabetes by up to five years in high-risk patients, marking the first therapy that actually modifies the disease instead of just managing symptoms. Scientists are now racing to develop additional treatments that protect insulin-producing cells before they're destroyed.
A groundbreaking treatment can now delay type 1 diabetes for up to three years, giving families precious time before symptoms begin. The NHS has approved the first-ever drug that stops the disease in its tracks during early stages.
Children across England and Wales can now access teplizumab, the groundbreaking drug that delays type 1 diabetes symptoms by three years. After decades of research, this immunotherapy treatment gives families precious extra time before daily insulin management begins.
The FDA just approved teplizumab for children aged 8 and older with stage 3 type 1 diabetes, expanding treatment options for young patients. This marks an important step forward in managing a disease that affects over 300,000 American children.
Groundbreaking therapies combining stem cells and immune drugs are showing real promise in helping people with type 1 diabetes produce their own insulin again. One patient has already delayed disease progression for nearly a decade.
A groundbreaking UK screening program is catching type 1 diabetes in children before it becomes an emergency, preventing potentially fatal hospital crises. More than 37,000 families have already joined the effort that's transforming childhood diabetes care.